GLP-1 Revolution
by Amaltash Advisors LLC
$96.50
-21.35% past month
Nov 16, 2026
$96.50-3.76%
Comparable listed companies in biological products fell 2.88% on average, with all 6 of 6 declining . The company's 3.76% drop came alongside that sector-wide weakness and was somewhat larger than the cohort average .
Nov 13, 2026
$100.27-0.40%
Comparable listed companies in Biological Products fell 0.81% on average, with 5 of 6 declining . The company's 0.40% decline came alongside that sector weakness and was smaller than the cohort average .
Nov 12, 2026
$100.67-0.99%
Comparable listed companies in biological products fell 3.54% on average, with 5 of 6 lower . The company's 0.99% decline came alongside that sector drop but was much smaller than the cohort average . Volume was 0.6x its trailing 20-session average, and the session traded in a range of 1.9% of the low .
Nov 11, 2026
$101.68-1.26%
Nov 10, 2026
$102.98+0.06%
Comparable listed companies in Biological Products moved -2.73% on average, with 5 of 6 falling . The company did not share in that weakness, closing up 0.06% .
Nov 9, 2026
$102.92-0.69%
Comparable listed companies in Biological Products rose 3.48% on average, with 5 of 6 advancing . HALO closed down 0.69%, so it moved against the cohort rather than with it .
Nov 6, 2026
$103.63-15.72%
Halozyme closed down 15.72%, while comparable biological products companies rose 1.57% on average, with all six of them up . The move was therefore not shared by the cohort. The Motley Fool's earnings call transcript summary pointed to Merck patent setbacks in the U.S. clouding an otherwise strong quarter for royalties . Volume was 2.8x the trailing 20-session average .
Closing prices for HALO. Summaries describe past sessions only and are not advice, a forecast or a recommendation.
Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.
Prices and financial data are historical and provided for research only. Not investment advice.
As of Nov 16, 2026, Halozyme Therapeutics, Inc. is 26.4% below its 52-week high. Its largest decline in the period shown was -49.1% (Dec 2, 2022 to May 8, 2023).
As of Nov 16, 2026, Halozyme Therapeutics, Inc. closed 26.4% below its 52-week closing high, set on Oct 29, 2026.
Halozyme Therapeutics, Inc. fell 49.1% from Dec 2, 2022 to May 8, 2023, close to close, the largest decline in daily data since Nov 18, 2021. It closed back above that high on Aug 19, 2024.
Learn how max drawdown is measured, and how past market drawdowns played out.
Daily closing prices from Nov 18, 2021 to Nov 16, 2026, adjusted for splits but not dividends. Past price movements do not predict future results.
How much would it be worth today? $1,000 invested in Halozyme Therapeutics, Inc. (HALO) 10 years ago, at the Nov 30, 2016 close, would be worth about $8,171 today, based on the Nov 16, 2026 close — a gain of $7,171 (+717.1%), dividends not included. Along the way it fell as much as 49.1% from a high, between Dec 2, 2022 and May 8, 2023. Before Nov 2021 this uses monthly highs and lows.
Return calculator
Worth today, at the Nov 16, 2026 close
$49,540
+$36,640 · +284.0%The cash line is the same deposits earning nothing. A savings account would usually have paid some interest.
Past performance of HALO's closing prices (split-adjusted; dividends not included). It ignores fees, taxes and trading costs. The results change as prices update and with the amounts you enter. Past results do not predict future results, and a single stock can fall hard. We show this for every asset in our directory; it is not a recommendation to buy or sell HALO.
Try the full investment calculatorThe coffee test
A $5 coffee every workday comes to about $100 a month. Over 5 years that's 1,200 coffees, or $6,000.
The same $100 a month put into HALO since November 2021 would be worth $11,790 today.
That's 2,358 coffees. Make it a large.
Past performance, month-end prices. Not a forecast.
| Invested | Start date | HALO price then | $1,000 → | $10,000 → | Change |
|---|---|---|---|---|---|
| 1 year | Nov 28, 2025 | $71.40 | $1,352 | $13,515 | +35.2% |
| 3 years | Nov 30, 2023 | $38.61 | $2,499 | $24,994 | +149.9% |
| 5 years | Nov 30, 2021 | $32.88 | $2,935 | $29,349 | +193.5% |
| 10 years | Nov 30, 2016 | $11.81 | $8,171 | $81,710 | +717.1% |
$10,000 invested in Halozyme Therapeutics, Inc. (HALO) at the Nov 30, 2016 close would have been worth about $81,710 at the Nov 16, 2026 close — a gain of $71,710 (+717.1%), dividends not included.
HALO closed at $11.81 on Nov 30, 2016 (split-adjusted). It closed at $96.50 on Nov 16, 2026.
Putting $100 into HALO at each month-end close from Nov 30, 2016 — 120 purchases, $12,000 in total — would have been worth about $42,186 at the Nov 16, 2026 close: a gain of $30,186 (+251.5%), dividends not included.
HALO closed at $96.50 on Nov 16, 2026. A year earlier it closed at $70.03 on Nov 14, 2025, so it is up 37.8% over that year. Five years earlier it closed at $38.07 on Oct 29, 2021 (up 153.5% since then). Its highest close in the year to Nov 16, 2026 was $131.18 on Oct 29, 2026, and its lowest was $61.63 on Mar 27, 2026. These are split-adjusted closing prices; dividends are not included.
HALO last closed at $96.50 on Nov 16, 2026. This page is updated once a day, so it does not show live prices.
Over one year, from $70.03 on Nov 14, 2025 to $96.50 on Nov 16, 2026, it was up 37.8%. Over five years, from $38.07 on Oct 29, 2021 to $96.50 on Nov 16, 2026, it was up 153.5%. These are split-adjusted closing prices; dividends are not included.
As of Nov 16, 2026, Halozyme Therapeutics, Inc. had a market value (market cap) of about $11.4 billion and a price-to-earnings (P/E) ratio of 32.
Halozyme makes a technology that helps injected medicines go under the skin quickly. It licenses this technology to other drug companies.
We do not tell anyone whether to buy or sell HALO, and past results do not predict future results. Its largest fall from a high since Nov 18, 2021 was 49.1%, from $59.44 on Dec 2, 2022 to $30.28 on May 8, 2023. A single stock can lose much of its value, so think about how much you could afford to lose. Our investment calculator shows how past amounts would have changed.
Past performance of HALO's closing prices. Not a forecast. This is general information, not a recommendation to buy or sell HALO.
Try the full investment calculatorThese strategies on Amaltash hold HALO today. We show them so you can see where it is used. This is not a recommendation to invest in any of them.
by Amaltash Advisors LLC